Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.
Saved in:
| Title: | Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial. |
|---|---|
| Authors: | Mai EK; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany., Nogai A; Medical Clinic for Hematology Oncology and Tumor Immunology, Charité Berlin Berlin Germany., Lokhorst HM; Department of Hematology VU University Medical Center Amsterdam The Netherlands., van der Holt B; HOVON, Rotterdam, The Netherlands and Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands., Zweegman S; Department of Hematology VU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands., Weisel KC; Medical Clinic and Polyclinic II University Hospital Hamburg-Eppendorf Hamburg Germany., Croockewit S; Department of Hematology Radboud University Medical Center Nijmegen The Netherlands., Jauch A; Institute of Human Genetics Medical Faculty Heidelberg, University of Heidelberg Heidelberg Germany., Hillengass J; Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USA., Stevens-Kroef M; Laboratorium Tumor Genetica Radboud University Medical Centre Nijmegen The Netherlands., Raab MS; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany., Broijl A; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands., Bos GMJ; Department of Internal Medicine University Hospital Maastricht Maastricht The Netherlands., Brossart P; Internal Medicine III, Oncology, Hematology and Rheumatology University Hospital Bonn Bonn Germany., Ypma P; Department of Hematology Haga Hospital The Hague The Netherlands., Hanoun C; Department of Hematology University Hospital Essen Essen Germany., Bertsch U; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany., Hielscher T; Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Heidelberg Germany., Salwender HJ; Department of Hematology and Oncology Asklepios Hospital Hamburg Altona Hamburg Germany., Scheid C; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn University of Cologne Cologne Germany., Goldschmidt H; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany.; National Center for Tumor Diseases (NCT) Heidelberg University Hospital Heidelberg Germany., Sonneveld P; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands. |
| Source: | HemaSphere [Hemasphere] 2024 Nov 20; Vol. 8 (11), pp. e70052. Date of Electronic Publication: 2024 Nov 20 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39569355 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Mai+EK%22">Mai EK</searchLink>; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany.<br /><searchLink fieldCode="AU" term="%22Nogai+A%22">Nogai A</searchLink>; Medical Clinic for Hematology Oncology and Tumor Immunology, Charité Berlin Berlin Germany.<br /><searchLink fieldCode="AU" term="%22Lokhorst+HM%22">Lokhorst HM</searchLink>; Department of Hematology VU University Medical Center Amsterdam The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Holt+B%22">van der Holt B</searchLink>; HOVON, Rotterdam, The Netherlands and Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands.<br /><searchLink fieldCode="AU" term="%22Zweegman+S%22">Zweegman S</searchLink>; Department of Hematology VU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands.<br /><searchLink fieldCode="AU" term="%22Weisel+KC%22">Weisel KC</searchLink>; Medical Clinic and Polyclinic II University Hospital Hamburg-Eppendorf Hamburg Germany.<br /><searchLink fieldCode="AU" term="%22Croockewit+S%22">Croockewit S</searchLink>; Department of Hematology Radboud University Medical Center Nijmegen The Netherlands.<br /><searchLink fieldCode="AU" term="%22Jauch+A%22">Jauch A</searchLink>; Institute of Human Genetics Medical Faculty Heidelberg, University of Heidelberg Heidelberg Germany.<br /><searchLink fieldCode="AU" term="%22Hillengass+J%22">Hillengass J</searchLink>; Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USA.<br /><searchLink fieldCode="AU" term="%22Stevens-Kroef+M%22">Stevens-Kroef M</searchLink>; Laboratorium Tumor Genetica Radboud University Medical Centre Nijmegen The Netherlands.<br /><searchLink fieldCode="AU" term="%22Raab+MS%22">Raab MS</searchLink>; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany.<br /><searchLink fieldCode="AU" term="%22Broijl+A%22">Broijl A</searchLink>; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands.<br /><searchLink fieldCode="AU" term="%22Bos+GMJ%22">Bos GMJ</searchLink>; Department of Internal Medicine University Hospital Maastricht Maastricht The Netherlands.<br /><searchLink fieldCode="AU" term="%22Brossart+P%22">Brossart P</searchLink>; Internal Medicine III, Oncology, Hematology and Rheumatology University Hospital Bonn Bonn Germany.<br /><searchLink fieldCode="AU" term="%22Ypma+P%22">Ypma P</searchLink>; Department of Hematology Haga Hospital The Hague The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hanoun+C%22">Hanoun C</searchLink>; Department of Hematology University Hospital Essen Essen Germany.<br /><searchLink fieldCode="AU" term="%22Bertsch+U%22">Bertsch U</searchLink>; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany.<br /><searchLink fieldCode="AU" term="%22Hielscher+T%22">Hielscher T</searchLink>; Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Heidelberg Germany.<br /><searchLink fieldCode="AU" term="%22Salwender+HJ%22">Salwender HJ</searchLink>; Department of Hematology and Oncology Asklepios Hospital Hamburg Altona Hamburg Germany.<br /><searchLink fieldCode="AU" term="%22Scheid+C%22">Scheid C</searchLink>; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn University of Cologne Cologne Germany.<br /><searchLink fieldCode="AU" term="%22Goldschmidt+H%22">Goldschmidt H</searchLink>; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany.; National Center for Tumor Diseases (NCT) Heidelberg University Hospital Heidelberg Germany.<br /><searchLink fieldCode="AU" term="%22Sonneveld+P%22">Sonneveld P</searchLink>; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101740619%22">HemaSphere</searchLink> [Hemasphere] 2024 Nov 20; Vol. 8 (11), pp. e70052. <i>Date of Electronic Publication: </i>2024 Nov 20 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101740619 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2572-9241 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225729241%22">25729241 </searchLink><i>NLM ISO Abbreviation: </i>Hemasphere <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39569355 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/hem3.70052 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e70052 Titles: – TitleFull: Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Mai EK – PersonEntity: Name: NameFull: Nogai A – PersonEntity: Name: NameFull: Lokhorst HM – PersonEntity: Name: NameFull: van der Holt B – PersonEntity: Name: NameFull: Zweegman S – PersonEntity: Name: NameFull: Weisel KC – PersonEntity: Name: NameFull: Croockewit S – PersonEntity: Name: NameFull: Jauch A – PersonEntity: Name: NameFull: Hillengass J – PersonEntity: Name: NameFull: Stevens-Kroef M – PersonEntity: Name: NameFull: Raab MS – PersonEntity: Name: NameFull: Broijl A – PersonEntity: Name: NameFull: Bos GMJ – PersonEntity: Name: NameFull: Brossart P – PersonEntity: Name: NameFull: Ypma P – PersonEntity: Name: NameFull: Hanoun C – PersonEntity: Name: NameFull: Bertsch U – PersonEntity: Name: NameFull: Hielscher T – PersonEntity: Name: NameFull: Salwender HJ – PersonEntity: Name: NameFull: Scheid C – PersonEntity: Name: NameFull: Goldschmidt H – PersonEntity: Name: NameFull: Sonneveld P IsPartOfRelationships: – BibEntity: Dates: – D: 20 M: 11 Text: 2024 Nov 20 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2572-9241 Numbering: – Type: volume Value: 8 – Type: issue Value: 11 Titles: – TitleFull: HemaSphere Type: main |
| ResultId | 1 |
